Pigmented villonodular synovitis is an uncommon benign neoplastic process that affects synovial-lined joints, bursae and tendon sheaths. We describe polyarticular extension of pigmented villonodular synovitis across joints secondary to pigmented villonodular tenosynovitis. Given that treatment is required to prevent progressive destruction of the involved joint, tendon or bursa, radiologists must be vigilant for diffuse polyarticular or extrasynovial involvement to optimize patient care and initiate appropriate therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180899PMC
http://dx.doi.org/10.1259/bjrcr.20150404DOI Listing

Publication Analysis

Top Keywords

pigmented villonodular
20
villonodular synovitis
12
polyarticular extension
8
extension pigmented
8
villonodular tenosynovitis
8
pigmented
5
villonodular
5
synovitis contiguous
4
contiguous joints
4
joints pigmented
4

Similar Publications

Synovial chondromatosis is a rare disorder characterized by cartilaginous growths within the joint lining, often confused with conditions like pigmented villonodular synovitis and rheumatoid arthritis. Primary treatment typically involves surgical synovectomy to remove the affected tissue and loose bodies. Documented cases are limited globally.

View Article and Find Full Text PDF

Introduction: A form of tenosynovial giant cell tumors (GCTs) that diffusely affects the soft tissue lining of joints and tendons is called pigmented villonodular synovitis or PVNS. About equal percentages of men and women are often affected, and it typically affects young individuals. The most typical sites of PVNS are the knee and ankle, making PVNS of the wrist a rare presentation.

View Article and Find Full Text PDF

Pigmented villonodular synovitis (PVNS) is rare in the shoulder, with few descriptions in the literature. We present the case of a 58-year-old female patient with no history of trauma. The patient reported pain for 2 months with no limb irradiation and presented lifting strength loss and progressive limitation of active and passive mobility.

View Article and Find Full Text PDF

Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT).

Expert Rev Anticancer Ther

December 2024

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.

Article Synopsis
  • Tenosynovial giant cell tumors (TGCTs) are aggressive tumors often found in younger individuals, leading to long-term disability and typically managed via surgery, which has its own risks.
  • This review focuses on systemic treatment options, particularly for the diffuse subtype (DT-TGCT), and assesses recent advancements and the historical context of these therapies.
  • Notable progress includes the development of CSF1 receptor-targeting therapies like pexidartinib, paving the way for further research on treatment effectiveness and optimizing patient outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!